Topiramate versus valproate sodium as adjunctive therapies to a combination of lithium and risperidone for adolescents with bipolar I disorder: Effects on weight and serum lipid profiles

Iranian Journal of Psychiatry

Volumn 7, Issue 1, 2012, Pages 1-10

  Mahmoudi Gharaei, Javad ^a   Shahrivar, Zahra ^a   Faghihi, Toktam ^b   Mohammadi, Mohammad Reza ^a   Tehrani Doost, Mehdi ^a   Alaghband Rad, Javad ^a   Ghaeli, Padideh ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Body weight; Lipids; Lithium; Risperidone; Topiramate; Valproate sodium

Indexed keywords

EID: 84865181375     PISSN: 17354587     EISSN: 20082215     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Smarty S and Findling RL. Psychopharmacology of pediatric bipolar disorder: a review. Psychopharmacology (Berl) 2007; 191: 39-54.
2. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 213-235.
3. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD and Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry 2008; 20: 131-137.
4. Garcia-Portilla MP, Saiz PA, Bascaran MT, Martinez AS, Benabarre A, Sierra P, et al. Cardiovascular risk in patients with bipolar disorder. J Affect Disord 2009; 115: 302-308.
5. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006; 67 Suppl 9: 25-30; discussion 36-42.
6. Sicras A, Rejas J, Navarro R, Serrat J and Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008; 10: 607-616.
7. van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342-348.
8. Scheffer RE and Linden S. Concurrent medical conditions with pediatric bipolar disorder. Curr Opin Psychiatry 2007; 20: 398-401.
9. Goldstein BI, Birmaher B, Axelson DA, Goldstein TR, Esposito-Smythers C, Strober MA, et al. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry 2008; 69: 1953-1959.
10. th eds. Saunders Elsevier Publications; 2007.
11. Zappalla FR and Gidding SS. Lipid management in children. Endocrinol Metab Clin North Am 2009; 38: 171-183.
12. Correll CU and Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45: 771-791.
13. Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 2008; 20: 195-201.
14. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007; 46: 687-700.
15. Tramontina S, Zeni CP, Pheula G and Rohde LA. Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: an open clinical trial. J Child Adolesc Psychopharmacol 2007; 17: 129-134.
16. Wagner KD, Redden L, Kowatch RA, Wilens TE, Segal S, Chang K, et al. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 2009; 48: 519-532.
17. Redden L, DelBello M, Wagner KD, Wilens TE, Malhotra S, Wozniak P, et al. Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder. J Child Adolesc Psychopharmacol 2009; 19: 83-89.
18. Delbello MP, Findling RL, Kushner S, Wang D, Olson WH, Capece JA, et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 539-547.
19. DelBello MP, Kowatch RA, Warner J, Schwiers ML, Rappaport KB, Daniels JP, et al. Adjunctive topiramate treatment for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 2002; 12: 323-330.
20. Kushner SF, Khan A, Lane R and Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006; 8: 15-27.
21. Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J and Rosenthal NR. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67: 1698-1706.
22. Fraguas D, Merchan-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008; 69: 1166-1175.
23. McIntyre RS and Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 2008; 162: 929-935.
24. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1: 1-93.
25. Patel NC, Hariparsad M, Matias-Akthar M, Sorter MT, Barzman DH, Morrison JA, et al. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol 2007; 17: 303-311.
26. Eiris J, Novo-Rodriguez MI, Del Rio M, Meseguer P, Del Rio MC and Castro-Gago M. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000; 41: 1-7.
27. Erdemir A, Cullu N, Yis U, Demircioglu F, Kir M, Cakmakci H, et al. Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev 2009; 31: 713-716.
28. Franzoni E, Verrotti A, Sarajlija J, Garone C, Matricardi S, Salerno GG, et al. Topiramate: effects on serum lipids and lipoproteins levels in children. Eur J Neurol 2007; 14: 1334-1337.
29. Pylvanen V, Pakarinen A, Knip M and Isojarvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006; 8: 643-648.
30. Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Shand BI, Scott RS. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust N Z J Psychiatry 2009; 43: 53-60.
31. Demircioglu S, Soylu A and Dirik E. Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children. Pediatr Neurol 2000; 23: 142-146.
32. Franzoni E, Govoni M, D'Addato S, Gualandi S, Sangiorgi Z, Descovich GC, et al. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia 1992; 33: 932-935.
33. Tekgul H, Demir N and Gokben S. Serum lipid profile in children receiving anti-epileptic drug monotherapy: is it atherogenic? J Pediatr Endocrinol Metab 2006; 19: 1151-1155.
34. Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 2009; 18: 418-428.
35. Bahk WM, Shin YC, Woo JM, Yoon BH, Lee JS, Jon DI, et al. Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 115-121.
36. Chengappa KN, Rathore D, Levine J, Atzert R, Solai L, Parepally H, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1: 42-53.
37. Mahmoudi Gharaei J, Alaghband-rad J, Faridhoseini F, Mohammadi MR, Tehranidoost M, Shahrivar Z, Ghaeli P, Faghihi T. Topiramate and sodium valproate as adjunctive therapy to lithium carbonate in treatment of bipolar disorder in adolescents: a randomized clinical trial. Iran J Psychiatry Clin Psychol 2008; 14: 122-130.
38. Friedewald WT, Levy RI and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
39. Eiris JM, Lojo S, Del Rio MC, Novo I, Bravo M, Pavon P, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995; 45: 1155-1157.
40. Grosso S, Mostardini R, Piccini B, Balestri P. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother 2009; 43: 45-50.
41. Karikas GA, Schulpis KH, Bartzeliotou A, Karakonstantakis T, Georgala S, Kanavaki I, et al. Lipids, lipoproteins, apolipoproteins, selected trace elements and minerals in the serum of children on valproic acid monotherapy. Basic Clin Pharmacol Toxicol 2006; 98: 599-603.
42. Malhi GS, Mitchell PB and Caterson I. 'Why getting fat, Doc?' Weight gain and psychotropic medications. Aust N Z J Psychiatry 2001; 35: 315-321.
43. Martin A and L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry 2002; 11: 129-133.
44. th eds. Saunders Elsevier Publications; 2007.
45. Aliyazicioglu R, Kural B, Colak M, Karahan SC, Ayvaz S, Deger O. Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder. Tohoku J Exp Med 2007; 213: 79-87.